BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2006

View Archived Issues

Active first quarter at Novo Nordisk

Read More

YM-529 inhibits bladder cancer cell growth

Read More

Safety and activity of CG-0070 in recurrent bladder cancer reported

Read More

Avanafil effective in men with mild to moderate erectile dysfunction

Read More

Study supports once-daily dosing of SLx-2101

Read More

Pretrial dosing begins with Conor Medsystems' dual-drug coronary stent

Read More

Jerini and Baxter report update on nonintravenous hemophilia therapy program

Read More

Novavax and Esprit to codevelop drug for female sexual desire disorder

Read More

Zenyth receives fourth milestone payment from Merck under asthma collaboration

Read More

Colorectal cancer patients included in phase I/II study of AP-12009

Read More

Phase IIa Atrigel/octreotide program in acromegaly delayed

Read More

Bavarian Nordic updates smallpox vaccine program

Read More

Phase II study begins for MK-0354 in patients with dyslipidemia

Read More

Phase II Oxycyte study in traumatic brain injury reaches treatment half-way post

Read More

CardioVascular BioTherapeutics achieves safety milestone in phase I heart trial

Read More

SRI awarded NIAID contract to produce oral formulations for antiradiation drugs

Read More

ConjuChem completes financing

Read More

Genzyme testing gene therapy for intermittent claudication

Read More

Fast track designation for Nektar's amphotericin B inhalation powder

Read More

Studies examine prolonged activity of once-daily tenatoprazole

Read More

Alvimopan improves gastrointestinal recovery after small bowel resection

Read More

Preclinical studies detail activity of asenapine

Read More

Recent patents cover novel analgesic agents

Read More

Novel agents for treating neurological disorders disclosed in recent patent literature

Read More

Recent patents describe new treatment options for endocrine-related disorders

Read More

The alpha7 nicotinic agonist AR-R17779 shows efficacy in a rat model of postoperative ileus

Read More

Intestinal inflammation may be reduced with cannabinoid receptor 2 agonists

Read More

Inhibition of heat shock protein 90 by KU-36 reduces prostate cancer proliferation

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing